Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy

Pharmacology and Therapeutics

Volumn 114, Issue 1, 2007, Pages 107-126

  Tamargo, Juan ^a   Caballero, Ricardo ^a   Gómez, Ricardo ^a   Núñez, Lucía ^a   Vaquero, Miguel ^a   Delpón, Eva ^a  

^a SCHOOL OF MEDICINE   (Spain)

Author keywords

Antiarrhythmic actions; Atrial fibrillation; Cardiac arrhythmias; Pleiotropic effects; Statins; Ventricular tachyarrhythmias

Indexed keywords

ACUTE PHASE PROTEIN; ALDOSTERONE ANTAGONIST; AMYLOID A PROTEIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; CALCIUM ION; CD18 ANTIGEN; CD40 LIGAND; CELL ADHESION MOLECULE; CHEMOKINE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1; INTERLEUKIN 18; INTERLEUKIN 6; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; POTASSIUM ION; PRAVASTATIN; SODIUM ION; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ATHEROSCLEROTIC PLAQUE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG DOSE COMPARISON; DRUG MECHANISM; HEART ARRHYTHMIA; HEART PROTECTION; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; ION TRANSPORT; MEMBRANE TRANSPORT; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOSIS PREVENTION; VASCULAR ENDOTHELIUM;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; HEART VENTRICLES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS;

EID: 34047154968     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2006.12.002     Document Type: Review

References (196)

1. Aikawa M., Rabkin E., Sugiyama S., Voglic S.J., Fukumoto Y., Furukawa Y., et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases, and tissue factor in vivo and in vitro. Circulation 103 (2001) 276-283
2. Albert M.A., Danielson E., Rifai N., Ridker P., and PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammtion/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 286 (2001) 64-70
3. Alberte C., and Zipes D.P. Use of nonantiarrhythmic drugs for prevention of sudden cardiac death. J Cardiovasc Electrophysiol 14 9 Suppl (2003) S87-S95
4. Amar D., Zhang H., Heerdt P.M., Park B., Fleisher M., and Thaler H.T. Statin use is associated with a reduction in atrial fibrillation after noncardiac thoracic surgery independent of C-reactive protein. Chest 128 (2005) 3421-3427
5. Anderson K.P. Lipid-lowering therapy for prevention of ventricular tachyarrhythmias. J Am Coll Cardiol 42 (2003) 88-92
6. Anderson J.L., Allen Maycock C.A., Lappe D.L., Crandall B.G., Horne B.D., Bair T.L., et al. Frequency of elevation of C-reactive protein in atrial fibrillation. Am J Cardiol 94 (2004) 1255-1259
7. Auer J., Weber T., Berent R., Lamm G., Ng C.K., Hartl P., et al. Use of HMG-coenzyme A-reductase inhibitors (statins) and risk reduction of atrial fibrillation after cardiac surgery: results of the SPPAF study: a randomised placebo-controlled trial. Eur Heart J 25 (2004) 353 (Suppl)
8. Avilés R.J., Martín D.O., Apperson-Hansen C., Hoghtaling P.L., Rautaharju P., Kronmal R.A., et al. Inflammation as a risk factor for atrial fibrillation. Circulation 108 (2003) 3006-3010
9. 2+ exchanger. FEBS Lett 343 (1994) 151-154
10. Bauersachs J., Galuppo P., Fraccarollo D., Christ M., and Ertl G. Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction. Circulation 104 (2001) 982-985
11. Bellosta S., Via D., Canavesi M., Pfister P., Fumagalli R., and Paoletti R. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 18 (1998) 1671-1678
12. Bettoni M., and Zimmermann M. Autonomic tone variations before the onset of paroxysmal atrial fibrillation. Circulation 105 (2002) 2753-2759
13. Bialecki R.A., and Tulenko T.N. Excess membrane cholesterol alters calcium channels in arterial smooth muscle. Am J Physiol 257 (1989) C306-C314
14. + channels and membrane fluidity in vascular smooth muscle cells. Pflügers Arch 415 (1989) 262-268
15. Bonetti P.O., Wilson S.H., Rodríguez-Porcel M., Holmes Jr. D.R., Lerman L.O., and Lerman A. Simvastatin preserves myocardial perfusion and coronary microvascular permeability in experimental hypercholesterolemia independent of lipid lowering. J Am Coll Cardiol 40 (2002) 546-554
16. Boos C.J., Anderson R.A., and Lip G.Y.H. Is atrial fibrillation an inflammatory disorder?. Eur Heart J 27 (2006) 136-149
17. Brown M., and Goldstein J. Sterol regulatory element binding proteins (SREBPs): controlers of lipid synthesis and cellular uptake. Nutr Rev 56 (1998) S1-S6
18. Bruins P., te Velthuis H., Yazdanbakhsh A.P., Jansen P.G., van Hardevelt F.W., de Beaumont E.M., et al. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation 96 (1997) 3542-3548
19. Bunch T.J., Kottke T.E., López-Jiménez F., Mahapatra S., Elesber A.A., and White R.D. A comparative analysis of short- and long-term outcomes after ventricular fibrillation out-of-hospital cardiac arrest in patients with ischemic and nonischemic heart disease. Am J Cardiol 98 (2006) 857-860
20. Bustos C., Hernández-Presa M., Ortego M., Tuñón J., Ortega L., Pérez F., et al. HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis. J Am Coll Cardiol 32 (1998) 2057-2064
21. Cai H., Li Z., Goette A., Mera F., Honeycutt C., Feterik K., et al. Downregulation of endocardial nitric oxide synthase expression and nitric oxide production in atrial fibrillation: potential mechanisms for atrial thrombosis and stroke. Circulation 106 (2002) 2854-2858
22. Cao J.M., Chen L.S., KenKnight B.H., Ohara T., Lee M.H., Tsai J., et al. Nerve sprouting and sudden cardiac death. Circ Res 86 (2000) 816-821
23. Cao J.M., Fishbein M.C., Han J.B., Lai W.W., Lai A.C., Wu T.J., et al. Relationship between regional cardiac hyperinnervation and ventricular arrhythmia. Circulation 101 (2000) 1960-1969
24. Caouette D., Dongmo C., Berube J., Fournier D., and Daleau P. Hydrogen peroxide modulates the Kv1.5 channel expressed in a mammalian cell line. Naunyn Schmiedebergs Arch Pharmacol 368 (2003) 479-486
25. Carnes C.A., Chung M.K., Nakayama T., Nakayama H., Baliga R.S., Piao S., et al. Ascorbate attenuates atrial pacing-induced peroxynitrite formation and electrical remodeling and decreases the incidence of postoperative atrial fibrillation. Circ Res 89 (2001) E32-E38
26. Chang H.M., Reitstetter R., Mason R.P., and Gruener R. Attenuation of channel kinetics and conductance by cholesterol: an interpretation using structural stress as a unifying concept. J Membr Biol 143 (1995) 51-63
27. Chen J., Nagasawa Y., Zhu B.M., Ohmori M., Harada K., Fujimura A., et al. Pravastatin prevents arrhythmias induced by coronary artery ischemia/reperfusion in anesthetized normocholesterolemic rats. J Pharmacol Sci 93 (2003) 87-94
28. Cheruku K.K., Ghani A., Ahmad F., Pappas P., Silverman P.R., Zelinger A., et al. Efficacy of nonsteroidal anti-inflammatory medications for prevention of atrial fibrillation following coronary artery bypass graft surgery. Prev Cardiol 7 (2004) 13-18
29. Cheung B.M., Lauder I.J., Lau C.-P., and Kumana C.R. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol 57 (2004) 640-651
30. Chiu J.H., Abdelhadi R.H., Chung M.K., Gurm H.S., Marrouche N.F., Saliba W.I., et al. Effect of statin therapy on risk of ventricular arrhythmia among patients with coronary artery disease and an implantable cardioverter-defibrillator. Am J Cardiol 95 (2005) 490-491
31. Cholesterol Treatment Trialists' Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366 (2005) 1267-1278
32. Christensen J.H., Toft E., Christensen M.S., and Schmidt E.B. Heart rate variability and plasma lipids in men with and without ischaemic heart disease. Atherosclerosis 145 (1999) 181-186
33. Chung M.K., Martin D.O., Sprecher D., Wazni O., Kanderian A., Carnes C.A., et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104 (2001) 2886-2891
34. Cinca J., Blanch P., Carreño A., Mont L., García-Burillo A., and Soler-Soler J. Acute ischemic ventricular arrhythmias in pigs with helaed myocardial infarction: comparative effects of ischemia at a distance and ischemia at the border zone. Circulation 96 (1997) 653-658
35. Colivicchi F., Guido V., Tubaro M., Ammirati F., Montefoschi N., Varvery A., et al. Effects of atorvastatin 80 mg daily early after onset of unstable angina pectoris or non-Q-wave myocardial infarction. Am J Cardiol 90 (2002) 872-874
36. Colivicchi F., Guido V., Ficili S., Mocini D., Ammirati F., and Santini M. Effects of statin therapy on the recurrence of persistent atrial fibrillation in patients with essential hypertension: a propensity score-adjusted analysis. Eur Heart J 25 (2004) S353 (Suppl)
37. Conti C.R. Updated pathophysiologic concepts in unstable coronary artery disease. Am Heart J 141 2 Suppl (2001) S12-S14
38. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., and Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103 (2001) 926-933
39. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 109 23 Suppl 1 (2004) III39-III43
40. De Sutter J., Tavernier R., De Buyzere M., Jordaens L., and De Backer G. Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol 36 (2000) 766-772
41. De Sutter J., De Bacquer D., Jordaens L., De Buyzere M., Matthys K., De Backer G., et al. Intensive lipid-lowering therapy and ventricular arrhythmias in patients with coronary artery disease and internal cardioverter defibrillators. Late Breaking Clinical Trials. Presented in the Heart Rhythm Society 2006 Annual Scientific Sessions; May 17-20, 2006; Boston, Massachusetts (2006)
42. Dechend R., Fiebeler A., Park J.K., Muller D.N., Theuer J., Mervaala E., et al. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Circulation 104 (2001) 576-581
43. Dernellis J., and Panaretou M. Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur Heart J 25 (2004) 1100-1107
44. Dernellis J., and Panaretou M. Effect of C-reactive protein reduction on paroxysmal atrial fibrillation. Am Heart J 150 (2005) 1064
45. Dotani M.I., Elnicki D.M., Jain A.C., and Gibson C.M. Effect of preoperative statin therapy and cardiac outcomes after coronary artery bypass grafting. Am J Cardiol 86 (2000) 1128-1130
46. Dupuis J., Tardif J.C., Cernacek P., and Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. Circulation 99 (1999) 3227-3233
47. Elvan A., Pride H.P., Eble J.N., and Zipes D.P. Radiofrequency catheter ablation of the atria reduces inducibility and duration of atrial fibrillation in dogs. Circulation 91 (1995) 2235-2244
48. Feron O., Dessy C., Desager J.P., and Balligand J.L. Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 103 (2001) 113-118
49. Folkeringa R.J., Van Kraaij D.J., Tieleman R.G., Nieman F.H., Pinto Y.M., and Crijns H.J. Statins associated with reduced mortality in patients admitted for congestive heart failure. J Card Fail 12 (2006) 134-138
50. Fonarow G.C., et al., for the National Registry of Myocardial Infarction 4 Investigators. Effect of statin use within the first 24 hours of admission for acute myocardial infarction on early morbidity and mortality. Am J Cardiol 96 (2005) 611-616
51. Fromer M., Genton C., Schlaepfer J., Goy J.J., and Kappenberger L. Is there an isolated arrhythmogenic right atrial myocarditis?. Eur Heart J 11 (1990) 566-571
52. Frustaci A., Chimenti C., Bellocci F., Morgante E., Russo M.A., and Maseri A. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 96 (1997) 1180-1184
53. Fukuda K., Davies S.S., Nakajima T., Ong B.H., Kupershmidt S., Fessel J., et al. Oxidative mediated lipid peroxidation recapitulates proarrhythmic effects on cardiac sodium channels. Circ Res 97 (2005) 1262-1269
54. Fukuta H., Sane D.C., Brucks S., and Little W.C. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 112 (2005) 357-363
55. Furukawa T., Moroe K., Mayrovitz H.N., Sampsell R., Furukawa N., and Myerburg R.J. Arrhythmogenic effects of graded coronary blood flow reductions superimposed on prior myocardial infarction in dogs. Circulation 84 (1991) 368-377
56. Fuster V., Rydén L.E., Cannom D.S., Crijns H.J., Curtis A.B., Ellenbogen K.A., et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114 (2006) e257-e354
57. Galis Z.S., Muszynski M., Sukhova G.K., Simon-Morrissey E., Unemori E.N., Lark M.W., et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res 75 (1994) 181-189
58. Gaudino M., Andreotti F., Zamparelli R., Di Castelnuovo A., Nasso G., Burzotta F., et al. The - 174G/C interleukin-6 polymorphism influences postoperative interleukin-6 levels and postoperative atrial fibrillation. Is atrial fibrillation an inflammatory complication?. Circulation 108 Suppl 1 (2003) II195-II199
59. Gleason M.M., Medow M.S., and Tulenko T.N. Excess membrane cholesterol alters calcium movements, cytosolic calcium levels, and membrane fluidity in arterial smooth muscle cells. Circ Res 69 (1991) 216-227
60. Goldberger J.J., et al., for the DEFINITE Investigators. Effects of statin therapy on arrhythmic events and survival in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol 48 (2006) 1228-1233
61. Gómez R., Núñez L., Vaquero M., Caballero R., Delpón E., and Tamargo J. Effects of atorvastatin on hKv1.5 and Kv4.3 potassium currents. Eur Heart J 26 (2005) 452 (Suppl)
62. Gottlieb S.S., McCarter R.J., and Vogel R.A. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 339 (1998) 489-497
63. Haigney M.C., Zareba W., Gentlesk P.J., Goldstein R.E., Illovsky M., McNitt S., et al. QT interval variability and spontaneous ventricular tachycardia or fibrillation in the Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients. J Am Coll Cardiol 44 (2004) 1481-1487
64. Hanna I.R., Heeke B., Bush H., Brosius L., King-Hageman D., and Dudley Jr. S.C. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm 3 (2006) 881-886
65. Hasin Y., Shimoni Y., Stein O., and Stein Y. Effect of cholesterol depletion on the electrical activity of rat heart myocytes in culture. J Mol Cell Cardiol 12 (1980) 675-683
66. Hayashidani S., Tsutsui H., Shiomi T., Suematsu N., Kinugawa S., Ide T., et al. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 105 (2002) 868-873
67. Holdgate G.A., Ward W.H., and McTaggart F. Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. Biochem Soc Trans 31 (2003) 528-531
68. Horwich T.B., MacLellan W.R., and Fonarow G.C. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 43 (2004) 642-648
69. Howes L.G., Abbott D., and Straznicky N.E. Lipoproteins and cardiovascular reactivity. Br J Clin Pharmacol 44 (1997) 319-324
70. Huikuri H.V., Jokinen V., Syvanne M., Nieminen M.S., Airaksinen K.E., Ikaheimo M.J., et al. Heart rate variability and progression of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 19 (1999) 1979-1985
71. Indolfi C., Di Lorenzo E., Perrino C., Stingone A.M., Curcio A., Torella D., et al. Hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. Circulation 106 (2002) 2118-2124
72. Jain M.K., and Ridker P.M. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 4 (2005) 977-987
73. Jialal I., Stein D., Balis D., Grundy S.M., Adams-Huet B., and Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103 (2001) 1933-1935
74. Karagueuzian H.S., Pennec J.P., Deroubaix E., de Leiris J., and Coraboeuf E. Effects of excess free fatty acids on the electrophysiological properties of ventricular specialized conducting tissue: a comparative study between the sheep and the dog. J Cardiovasc Pharmacol 4 (1982) 462-468
75. Katchman A., Koerner J., Tosak A.T., Woosley R., and Ebert S. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Ther 316 (2006) 1098-1106
76. + channels induced by HMG CoA reductase inhibitor in ischemic rabbit hearts. Hypertens Res 24 (2001) 573-577
77. Kayikcioglu M., Can L., Evrengul H., Payzin S., and Kultursay H. The effect of statin therapy on ventricular late potentials in acute myocardial infarction. Int J Cardiol 90 (2003) 63-72
78. Kim Y.M., Guzik T.J., Zhang Y.H., Zhang M.H., Kattach H., Ratnatunga C., et al. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ Res 97 (2005) 629-636
79. Kjekshus J., Pedersen T.R., Olsson A.G., Faergeman O., and Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 3 (1997) 249-254
80. Kolvekar S., D'Souza A., Akhtar P., Reek C., Garratt C., and Spyt T. Role of atrial ischemia in development of atrial fibrillation following coronary artery bypass surgery. Eur J Cardiothorac Surg 11 (1997) 70-75
81. Krum H., and McMurray J.J. Statins and chronic heart failure: do we need a large-scale outcome trial?. J Am Coll Cardiol 39 (2002) 1567-1573
82. Kumagai K., Nakashima H., and Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 62 (2004) 105-111
83. Kutryk M.J., and Pierce G.N. Stimulation of sodium-calcium exchange by cholesterol incorporation into isolated cardiac sarcolemmal vesicles. J Biol Chem 263 (1988) 13167-13172
84. Lamers J.M., Hartog J.M., Verdouw P.D., and Hulsmann W.C. Dietary fatty acids and myocardial function. Basic Res Cardiol 82 Suppl 1 (1987) 209-221
85. Landmesser U., and Drexler H. The clinical significance of endothelial dysfunction. Curr Opin Cardiol 20 (2005) 547-551
86. Laufs U., Wassmann S., Hilgers S., Ribaudo N., Bohm M., and Nickenig G. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, noncholesterolemic men. Am J Cardiol 88 (2001) 1306-1307
87. Laufs U., Custodis F., and Böhm M. HMG-CoA reductase inhibitors in chronic heart failure. Drugs 66 (2006) 146-154
88. Lee T.M., Chou T.F., and Tsai C.H. Association of pravastatin and left ventricular mass in hypercholesterolemic patients: role of 8-iso-prostaglandin f2alpha formation. J Cardiovasc Pharmacol 40 (2002) 868-874
89. Lee T.M., Chou T.F., and Tsai C.H. Effects of pravastatin on cardiomyocyte hypertrophy and ventricular vulnerability in normolipidemic rats after myocardial infarction. J Mol Cell Cardiol 35 (2003) 1449-1459
90. ATP channels in hypercholesterolemic rabbits. Atherosclerosis 176 (2004) 273-278
91. Lee T.M., Lin M.S., Chou T.F., and Chang N.C. Effect of simvastatin on left ventricular mass in hypercholesterolemic rabbits. Am J Physiol Heart Circ Physiol 288 (2005) H1352-H1358
92. Lee T.M., Lin M.S., Chou T.F., Tsai C.H., and Chang N.C. Effect of pravastatin on development of left ventricular hypertrophy in spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 289 (2005) H220-H227
93. Lefer A.M., Campbell B., Shin Y.J., Scalia R., Hayward R., and Lefer D.J. Simvastatin preserves the ischemic-reperfused myocardium in normocholesterolemic rat hearts. Circulation 100 (1999) 178-184
94. Lefer D.J., Scalia R., Jones S.P., Sharp B.R., Hoffmeyer M.R., Farvid A.R., et al. HMG-CoA reductase inhibition protects the diabetic myocardium from ischemia-reperfusion injury. FASEB J 15 (2001) 1454-1456
95. Levy D., Garrison R.J., Savage D.D., Kannel W.B., and Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322 (1990) 1561-1566
96. Li L., Matsuoka I., Suzuki Y., Watanabe Y., Ishibashi T., Yokoyama K., et al. Inhibitory effect of fluvastatin on lysophosphatidylcholine-induced nonselective cation current in guinea pig ventricular myocytes. Mol Pharmacol 62 (2002) 602-607
97. Liao J.K., and Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 45 (2005) 89-118
98. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104 (2001) 365-372
99. Lijnen P., and Petrov V. Cholesterol modulation of transmembrane cation transport systems in human erythrocytes. Biochem Mol Med 56 (1995) 52-62
100. Lijnen P., Celis H., Fagard R., Staessen J., and Amery A. Influence of cholesterol lowering on plasma membrane lipids and cationic transport systems. J Hypertens 12 (1994) 59-64
101. Liu Y.B., Wu C.C., Lu L.S., Su M.J., Lin C.W., Lin S.F., et al. Sympathetic nerve sprouting, electrical remodeling, and increased vulnerability to ventricular fibrillation in hypercholesterolemic rabbits. Circ Res 92 (2003) 1145-1152
102. Locher R., Neyses L., Stimple M., Kuffer B., and Vetter W. The cholesterol content of the human erythrocyte influences calcium influx through the channel. Biochem Biophys Res Commun 124 (1984) 822-828
103. López-Sendón J., Swedberg K., McMurray J., Tamargo J., Maggioni A.P., Dargie H., et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J 25 (2004) 1341-1362
104. Lorenz H., Junger C., Seidl K., Gitt A., Schneider S., Schiele R., et al. Do statins influence the prognostic impact of non-sustained ventricular tachycardia after ST-elevation myocardial infarction?. Eur Heart J 26 (2005) 1078-1085
105. Luan Z., Chase A.J., and Newby A.C. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 23 (2003) 769-775
106. Maack C., Kartes T., Kilter H., Schafers H.J., Nickenig G., Bohm M., et al. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 108 (2003) 1567-1574
107. Maixent J.M., Paganelli F., Scaglione J., and Levy S. Antibodies against myosin in sera of patients with idiopathic paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 9 (1998) 612-617
108. Marín F., Pascual D.A., Roldán V., Arribas J.M., Ahumada M., Tornel P.L., et al. Statins and postoperative risk of atrial fibrillation following coronary artery bypass grafting. Am J Cardiol 97 (2006) 55-60
109. Mark L., and Katona A. Effect of fluvastatin on QT dispersion: a new pleiotropic effect?. Am J Cardiol 85 (2000) 919-920
110. Martens J.R., O'Connell K., and Tamkun M. Targeting of ion channels to membrane microdomains: localization of Kv channels to lipid rafts. Trends Pharmacol Sci 25 (2004) 16-21
111. Mason R.P., Walter M.F., and Jacob R.F. Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress. Circulation 109 21 Suppl 1 (2004) II34-II41
112. Mehta D., Curwin J., Gomes J.A., and Fuster V. Sudden death in coronary artery disease: acute ischemia versus myocardial substrate. Circulation 96 (1997) 3215-3223
113. Mendes L.A., Connelly G.P., McKenney P.A., Podrid P.J., Cupples L.A., Shemin R.J., et al. Right coronary artery stenosis: an indepedent predictor of atrial fibrillation after coronary artery bypass surgery. J Am Coll Cardiol 25 (1995) 198-202
114. Merckx L., Tieleman R.G., Folkeringa R.J., Pinto Y.M., Niemanm F.H., Cheriex E.C., et al. Use of statins is associated with reduced incidence of atrial fibrillation in patients with left ventricular hypertrophy and left atrial dilatation. Heart Rhythm 1 1 Suppl 1 (2004) S105
115. Mihm M.J., Yu F., Carnes C.A., Reiser P.J., McCarthy P.M., Van Wagoner D.R., et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 104 (2001) 174-180
116. Mitchell L.B., Powell J.L., Gillis A.M., Kehl V., Hallstrom A.P.,, and AVID Investigators. Are lipid-lowering drugs also antiarrhythmic drugs? An analysis of the antiarrhythmics versus implantable defibrillators (AVID) trial. J Am Coll Cardiol 42 (2003) 81-87
117. Mukai Y., Shimokawa H., Matoba T., Hiroki J., Kunihiro I., Fujiki T., et al. Acute vasodilator effects of HMG-CoA reductase inhibitors: involvement of PI3-kinase/Akt pathway and Kv channels. J Cardiovasc Pharmacol 42 (2003) 118-124
118. Nattel S. New ideas about atrial fibrillation 50 years on. Nature 415 (2002) 219-226
119. Node K., Fujita M., Kitakaze M., Hori M., and Liao J.K. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 108 (2003) 839-843
120. O'Connell S., and Tamkun M.M. Targeting of voltage-gated potassium channel isoforms to distinct cell surface microdomains. J Cell Sci 118 (2005) 2155-2166
121. Oi S., Haneda T., Osaki J., Kashiwagi Y., Nakamura Y., Kawabe J., et al. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. Eur J Pharmacol 376 (1999) 139-148
122. 2+)-ATPase from cardiac muscle. Biochim Biophys Acta 773 (1984) 231-236
123. Ozaydin M., Varol E., Aslan S.M., Kucuktepe Z., Dogan A., Ozturk M., et al. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion. Am J Cardiol 97 (2006) 1490-1493
124. Pandit S.V., Berenfeld O., Anumonwo J.M., Zaritski R.M., Kneller J., Nattel S., et al. Ionic determinants of functional reentry in a 2-D model of human atrial cells during simulated chronic atrial fibrillation. Biophys J 88 (2005) 3806-3821
125. Patti G., Chello M., Candura D., Pasceri V., D'Ambrosio A., Covino E., et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study. Circulation 114 (2006) 1455-1461
126. Pehlivanidis A.N., Athyros V.G., Demitriadis D.S., Papageogiou A.A., Bouloukos V.J., and Kontopoulos A.G. Heart rate variability after long-term treatment with atorvastatin in hypercholesterolaemic patients with or without coronary artery disease. Atherosclerosis 157 (2001) 463-469
127. -/- mice in vivo. Circulation 107 (2003) 2480-2486
128. Pfeffer M.A., and Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 81 (1990) 1161-1172
129. Pliquett R.U., Cornish K.G., Peuler J.D., and Zucker I.H. Simvastatin normalizes autonomic neural control in experimental heart failure. Circulation 107 (2003) 2493-2498
130. Pound E.M., Kang J.X., and Leaf A. Partitioning of polyunsaturated fatty acids, which prevent cardiac arrhythmias, into phospholipid cell membranes. J Lipid Res 42 (2001) 346-351
131. Pratt C.M., Waldo A.L., and Camm A.J. Can antiarrhythmic drugs survive survival trials?. Am J Cardiol 81 (1998) 24D-34D
132. Quinn P.J. The fluidity of cell membranes and its regulation. Prog Biophys Mol Biol 38 (1981) 1-104
133. Quintana M., Storck N., Lindblad L.E., Lindvall K., and Ericson M. Heart rate variability as a means of assessing prognosis after acute myocardial infarction. A 3-year follow-up study. Eur Heart J 18 (1997) 789-797
134. Raina A., Pickering T., and Shimbo D. Statin use in heart failure: a cause for concern?. Am Heart J 152 (2006) 39-49
135. Ray K.K., and Cannon C.P. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 46 (2005) 1425-1433
136. Ren Y.J., Xu X.H., Zhong C.B., Feng N., and Wang X.L. Hypercholesterolemia alters vascular functions and gene expression of potassium channels in rat aortic smooth muscle cells. Acta Pharmacol Sin 22 (2001) 274-278
137. Riahi S., Christensen J.H., Toft E., Skou H.A., and Schmidt E.B. HMG-CoA reductase inhibitors improve heart rate variability in patients with a previous myocardial infarction. Pharmacol Res 45 (2002) 479-483
138. Ridker P.M. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103 (2001) 1813-1818
139. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F., and Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 100 (1999) 230-235
140. Ridker P.M., et al., for the Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 344 (2001) 1959-1965
141. Rikitake Y., Kawashima S., Takeshita S., Yamashita T., Azumi H., Yasuhara M., et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 154 (2001) 87-96
142. + current by optical isomers of cholesterol. Biophys J 83 (2002) 3211-3222
143. Rubart M., and Zipes D.P. Mechanisms of sudden cardiac death. J Clin Invest 115 (2005) 2305-2315
144. Sacks F.M., Pfeffer M.A., Moye L.A., Brown L.E., Hamm P., Cole T.G., et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
145. Sasaki N., Sato T., Ohler A., O'Rourke B., and Marbán E. Activation of mitochondrial ATP-dependent potassium channels by nitric oxide. Circulation 101 (2000) 439-445
146. Scalia R., Gooszen M.E., Jones S.P., Hoffmeyer M., Rimmer III D.M., and Trocha S.D. Simvastatin exerts both anti-inflammatory and cardioprotective effects in apolipoprotein E-deficient mice. Circulation 103 (2001) 2598-2603
147. Scandinavian Survival Study Group. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
148. Schauerte P., Scherlag B.J., Pitha J., Scherlag M.A., Reynolds D., Lazzara R., et al. Catheter ablation of cardiac autonomic nerves for prevention of vagal atrial fibrillation. Circulation 102 (2000) 2774-2780
149. Schonbeck U., and Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents?. Circulation 109 21 Suppl 1 (2004) II18-II26
150. Schwartz G., Olsson A., Ezekowitz M., Ganz P., Oliver M.F., Waters D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: a randomized trial. JAMA 285 (2001) 1711-1718
151. + channels. Prog Biophys Mol Biol 81 (2003) 133-176
152. Shioiri H., Komaru T., Sato K., Takahashi K., Takeda S., Kanatsuka H., et al. Impact of hypercholesterolemia on acidosis-induced coronary microvascular dilation. Basic Res Cardiol 98 (2003) 76-83
153. Shiroshita-Takeshita A., Schram G., Lavoie J., and Nattel S. Effect of simvastatin and antioxidant vitamins on atrial fibrillation promotion by atrial-tachycardia remodeling in dogs. Circulation 110 (2004) 2313-2319
154. Shusterman V., Aysin B., Gottipaty V., Weiss R., Brode S., Schwartzman
155. Sinno H., Derakhchan K., Libersan D., Merhi Y., Leung T.K., and Nattel S. Atrial ischemia promotes atrial fibrillation in dogs. Circulation 107 (2003) 1930-1936
156. Siu C.W., Lau C.P., and Tse H.F. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol 92 (2003) 1343-1345
157. Sobel B.E., Corr P.B., Robinson A.K., Goldstein R.A., Witkowski F.X., and Lein M.S. Accumulation of lysophosphoglycerides with arrhythmogenic properties in ischemic myocardium. J Clin Invest 62 (1978) 546-553
158. Sola S., Mir M.Q., Rajagopalan S., Helmy T., Tandon N., and Khan B.V. Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure. J Card Fail 11 (2005) 607-612
159. Sola S., Mir M.Q., Lerakis S., Tandon N., and Khan B.V. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 47 (2006) 332-337
160. Sorescu D., and Griendling K.K. Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest Heart Fail 8 (2002) 132-140
161. Sukhova G.K., Williams J.K., and Libby P. Statins reduce inflammation in atheroma of nonhuman primates independent of effects on serum cholesterol. Arterioscler Thromb Vasc Biol 22 (2002) 1452-1458
162. Sundstrom J., Lind L., Vessby B., Andren B., Aro A., and Lithell H. Dyslipidemia and an unfavorable fatty acid profile predict left ventricular hypertrophy 20 years later. Circulation 103 (2001) 836-841
163. Suzumura K., Yasuhara M., Tanaka K., and Suzuki T. Protective effect of fluvastatin sodium (XU-62-320), a 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, on oxidative modification of human low-density lipoprotein in vitro. Biochem Pharmacol 57 (1999) 697-703
164. Szmitko P.E., Wang C.H., Weisel R.D., Jeffries G.A., Anderson T.J., and Verma S. Biomarkers of vascular disease linking inflammation to endothelial activation, Part I. Circulation 108 (2003) 1917-1923
165. Takemoto M., Node K., Nakagami H., Liao Y., Grimm M., Takemoto Y., et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 108 (2001) 1429-1437
166. Tamargo J., Caballero R., and Delpón E. Phamacological approach in the treatment of atrial fibrillation. Curr Med Chem 11 (2004) 13-28
167. Tamargo J., Caballero R., Gómez R., Valenzuela C., and Delpón E. Pharmacology of cardiac potassium channels. Cardiovasc Res 62 (2004) 9-33
168. Terata Y., Saito T., Fujiwara Y., Hasegawa H., Miura H., Watanabe H., et al. Pitavastatin inhibits upregulation of intermediate conductance calcium-activated potassium channels and coronary arteriolar remodeling induced by long-term blockade of nitric oxide synthesis. Pharmacology 68 (2003) 169-176
169. 2+ release and vascular reactivity. J Cardiovasc Pharmacol 34 (1999) 95-101
170. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339 (1998) 1349-1357
171. Tomaselli G.F., and Zipes D.P. What causes sudden death in heart failure?. Circ Res 95 (2004) 754-763
172. Tomita T., Takei M., Saikawa Y., Hanaoka T., Uchikawa S., Tsutsui H., et al. Role of autonomic tone in the initiation and termination of paroxysmal atrial fibrillation in patients without structural heart disease. J Cardiovasc Electrophysiol 14 (2003) 559-564
173. Tulenko T.N., Bialecki R., Gleason M., and D'Angelo G. Ion channels, membrane lipids and cholesterol: a role for membrane lipid domains in arterial function. Prog Clin Biol Res 334 (1990) 187-203
174. Tveit A., Grundtvig M., Gundersen T., Vanberg P., Semb A.G., Holt E., et al. Analysis of pravastatin to prevent recurrence of atrial fibrillation after electrical cardioversion. Am J Cardiol 93 (2004) 780-782
175. Ueda Y., Kitakaze M., Komamura K., Minamino T., Asanuma H., Sato H., et al. Pravastatin restored the infarct size-limiting effect of ischemic preconditioning blunted by hypercholesterolemia in the rabbit model of myocardial infarction. J Am Coll Cardiol 34 (1999) 2120-2125
176. Van Boven A.J., Jukema J.W., Crijns H.J., and Lie K.I. Heart rate variability profiles in symptomatic coronary artery disease and preserved left ventricular function: relation to ventricular tachycardia and transient myocardial ischemia. Regression Growth Evaluation Statin Study (REGRESS). Am Heart J 130 (1995) 1020-1025
177. Van Boven A.J., Jukema J.W., Zwindermann A.H., Crijns H.J., Lie K.I., and Bruschke A.V. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. REGRESS Study Group. Circulation 94 (1996) 1503-1505
178. Vaquero M., Núñez L., Gómez R., Caballero R., Delpón E., and Tamargo J. Efectos de la atorvastatina sobre las corrientes de potasio responsables de la repolarización auricular humana, hKv1.5 y Kv4.3. Rev Esp Cardiol 58 Suppl 1 (2005) 130
179. Vaquero M., Núñez L., Gómez R., Caballero R., Delpón E., and Tamargo J. Effects of simvastatin on cardiac hKv1.5, Kv4.3, and calcium currents. Methods Find Exp Clin Pharmacol 28 (2006) 76
180. +-overload in isolated cardiomyocytes and effect of cytoprotective drugs. J Mol Cell Cardiol 24 (1992) 977-988
181. Vrtovec B., Okrajsek R., Golicnik A., Ferjan M., Starc V., and Radovancevic B. Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure. J Card Fail 11 (2005) 684-690
182. Vyas A., et al., for the MADIT-II Research Group. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 47 (2006) 769-773
183. Wagner A.H., Köhler T., Rückschloss U., Just I., and Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 20 (2000) 61-69
184. Wassmann S., and Nickenig G. Improvement of endothelial function by HMG-CoA reductase inhibitors. Drug News Perspect 15 (2002) 85-92
185. Wassmann S., Laufs U., Muller K., Konkol C., Ahlbory K., and Baumer A.T. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 22 (2002) 300-305
186. Welzig C.M., Shin D.G., Park H.J., Kim Y.J., Saul J.P., and Galper J.B. Lipid lowering by pravastatin increases parasympathetic modulation of heart rate: Galpha(i2), a possible molecular marker for parasympathetic responsiveness. Circulation 108 (2003) 2743-2746
187. Wijffels M., and Crijns H.J. Recent advances in drug therapy for atrial fibrillation. J Cardiovasc Electrophysiol 14 9 Suppl (2003) S40-S47
188. Williams J.K., Sukhova G.K., Herrington D.M., and Libby P. Pravastatin has cholesterol-lowering independent effects on the artery wall of atherosclerotic monkeys. J Am Coll Cardiol 31 (1998) 684-691
189. Wolf P.A., Abbott R.D., and Kannel W.B. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch Intern Med 147 (1987) 1561-1564
190. Wu C.C., Su M.J., Chi J.F., Chen W.J., Hsu H.C., and Lee Y.T. The effect of hypercholesterolemia on the sodium inward currents in cardiac myocyte. J Mol Cell Cardiol 27 (1995) 1263-1269
191. Yamazaki M., Suzuki H., Hanano M., and Sugiyama Y. Different relationships between cellular ATP and hepatic uptake among taurocholate, cholate, and organic anions. Am J Physiol 264 (1993) G693-G701
192. Yeagle P.L. Modulation of membrane function by cholesterol. Biochimie 73 (1991) 1303-1310
193. +)-ATPase ATP hydrolyzing activity in bovine kidney. Biochemistry 27 (1988) 6449-6452
194. Yokoyama K., Ishibashi T., Ohkawara H., Kimura J., Matsuoka I., Sakamoto T., et al. HMG-CoA reductase inhibitors suppress intracellular calcium mobilization and membrane current induced by lysophosphatidylcholine in endothelial cells. Circulation 105 (2002) 962-967
195. Young-Xu Y., Jabbour S., Goldberg R., Blatt C.M., Graboys T., Bilchik B., et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol 92 (2003) 1379-1383
196. Zipes D.P., and Wellens H.J. Sudden cardiac death. Circulation 98 (1998) 2334-2351